ERBB2 and breast carcinoma: Based on current preclinical and clinical evidence, the primary target population for KAT6 inhibitors is expected to be patients with ER+/HER2− breast cancer. ER+/HER2− breast cancer represents the most prevalent subtype, accounting for approximately 60% of all cases [236].